Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.46 |
| ▸ | KHK | P50053 | 1/20 | 0.41 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121641 | 0.83 | TDP1 (0.46) | NQO1KHKPGK1KDM4EALDH1A1 | |
| SCHEMBL29558664 | 0.83 | TDP1 (0.46) | NQO1KHKPGK1KDM4EALDH1A1 | |
| SCHEMBL4921900 | 0.81 | GLP1R (0.52) | NQO1GLP1RPGK1KDM4EALDH1A1 | |
| SCHEMBL1138232 | 0.79 | KDM4E (0.48) | NQO1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL119791 | 0.79 | KDM4E (0.48) | NQO1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL18585748 | 0.78 | KDM4E (0.47) | NQO1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL121613 | 0.77 | CYP3A4 (0.48) | NQO1GLP1RPGK1KDM4EALDH1A1 | |
| SCHEMBL7698365 | 0.76 | NQO2 (0.50) | NQO1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL1138685 | 0.74 | PIK3CG (0.55) | NQO1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL5023733 | 0.73 | ALDH1A1 (0.35) | PGK1KDM4EALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424537-B1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER IP GMBH (DE) | 2015-07-08 | — | — | EP | disclosed |
| EP-2424537-B1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER IP GMBH (DE) | 2015-07-08 | — | — | EP | disclosed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-8729082-B2 | Substituted imidazoquinoxalines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-8598173-B2 | 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-12-03 | — | — | US | disclosed |
| US-20130053390-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | REXAHN PHARMACEUTICALS, INC. | 2013-02-28 | — | — | US | disclosed |
| US-8314100-B2 | 1-[6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives | REXAHN PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| EP-2424537-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | Bayer Pharma Aktiengesellschaft (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010124826-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010124826-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-04 | — | — | WO | disclosed |
| US-20080318963-A1 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives | REXAHN PHARMACEUTICALS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318963-A1 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives | HRAS, CDK4, KRAS | NQO1 91/4885KHK 2036/4885GLP1R 3532/4885 |
| US-20120128662-A1 | SUBSTITUTED IMIDAZOQUINOXALINES | TTBK1, TTK, TTBK2 | NQO1 1850/4885KHK 1107/4885GLP1R 4390/4885 |
| US-20130053390-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | HRAS, CDK4, KRAS | NQO1 63/4885KHK 2489/4885GLP1R 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.